Although we observed an association of genetically proxied ABCC8 inhibition on the outcome, it is not known whether ABCC8 agonists directly alter POAG risk independent of their impact on blood glucose levels and the clinical effects of these medications on nondiabetic populations or patients with normal IOP remain unknown. Here, ABCC8 is linked to open-angle glaucoma.